If you want to get an idea of where PYC should be then look at EGX.
They're hitting PYC for six in terms of securing collaborative agreements, out-licensing and internal development.
If PYC's 'phylomers' do have an advantage over antibodies then they'll do well. You only have to read up on Avidia, Cambridge Antibody Technologies and Domantis to realise there's lots of money in this field.
However IMO, I think EGX is a lot closer to joining the list of companies mentioned above than PYC is.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.36 |
Change
0.005(0.37%) |
Mkt cap ! $793.2M | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.40 | $1.36 | $211.9K | 152.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4103 | $1.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 2028 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |